HEARTWARE INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against HeartWare International, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased or otherwise acquired the common stock of HeartWare International, Inc. (“HeartWare” or the “Company”) (Nasdaq:HTWR) between June 10, 2014 and January 11, 2016, inclusive (the “Class Period”).

If you purchased or acquired HeartWare common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than March 22, 2016. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

HeartWare investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

The action alleges that, throughout the Class Period, defendants falsely claimed to have addressed numerous manufacturing and other regulatory failures identified by the U.S. Food and Drug Administration (“FDA”) regarding HeartWare’s Miniaturized Ventricular Assist Device (“MVAD”).

On September 1, 2015, HeartWare revealed major problems that would impede the advancement of MVAD’s approval. On this news, HeartWare’s stock price fell nearly 21%, to close at $64.82 per share on September 2, 2015.

On October 12, 2015 HeartWare disclosed that patients in the MVAD trial had suffered adverse events and that the trial would be further delayed. On this news, HeartWare’s stock price fell nearly 30%, to close at $35.21 per share on October 13, 2015.

On January 11, 2016, HeartWare admitted that problems with the MVAD had resulted in major problems in nearly half the patients in the trial who had been implanted with the device and that the trial would be suspended until further notice. On this news, HeartWare stock price dropped over 35%, to close at $26.50 per share on January 12, 2016.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP is a nationally recognized law firm committed to advancing investor rights and promoting corporate responsibility.

For thirteen years, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs’ law firms in the nation. Best Lawyers and U.S. News have also named Lieff Cabraser as a “Law Firm of the Year” each year the publications have given this award to law firms.

For more information about Lieff Cabraser and the firm’s representation of investors, please visit http://www.lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Source/Contact for Media Inquiries Only:
Lieff Cabraser Heimann & Bernstein, LLP
Sharon M. Lee, 800-541-7358

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.